Medicine & Life Sciences
Breast Neoplasms
100%
Trastuzumab
72%
Lapatinib
43%
Drug Therapy
30%
Anthracyclines
23%
taxane
21%
human ERBB2 protein
20%
Triple Negative Breast Neoplasms
19%
Disease-Free Survival
18%
ixabepilone
18%
Paclitaxel
17%
Neoplasms
17%
etirinotecan pegol
16%
Therapeutics
16%
Survival
14%
Capecitabine
11%
Adjuvant Chemotherapy
11%
Heterografts
9%
Albumin-Bound Paclitaxel
9%
Progression-Free Survival
9%
B 31
9%
Neoadjuvant Therapy
9%
130-nm albumin-bound paclitaxel
8%
Taxoids
8%
Recurrence
8%
Peripheral Nervous System Diseases
6%
Sorafenib
6%
Nanoparticles
6%
Safety
6%
Bevacizumab
6%
Carboplatin
6%
Myelodysplastic Syndromes
6%
Neoplasm Metastasis
6%
Hormones
5%
Breast
5%
Platelet Count
5%
Cardiotoxicity
5%
Diarrhea
5%
Biopsy
5%
pixantrone
5%
pertuzumab
5%